Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to NeoGenomics, Inc. (NASDAQ: NEO) SEC filings, offering a regulatory view of the company’s activities as a public cancer diagnostics business. NeoGenomics is a Nevada corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol NEO, as disclosed in its Form 8-K filings.
Investors can review current reports on Form 8-K, which NeoGenomics uses to furnish quarterly financial results, preliminary revenue updates, and information about board and executive changes. Recent 8-K filings have reported results for fiscal quarters, described financial metrics such as revenue and operating expenses, and documented director appointments and resignations.
Through this page, users can also monitor quarterly and annual reports (Forms 10-Q and 10-K when available) that typically include detailed discussions of the company’s oncology diagnostics operations, risk factors, and financial statements. These filings complement the company’s news releases describing clinical test volumes, next-generation sequencing contributions, and research and development spending.
For those tracking governance and corporate actions, the SEC filings detail matters such as board composition and compensation arrangements for directors, as reflected in 8-K disclosures about board changes. Filings related to financial results often reference non-GAAP measures like Adjusted EBITDA and Adjusted Gross Profit Margin, with reconciliations and definitions included in the attached press releases.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes from prior periods, and make it easier to locate items related to revenue trends, operating performance, and governance updates. Real-time updates from EDGAR help ensure that new NeoGenomics filings, including any future Forms 10-K, 10-Q, or Form 4 insider transaction reports, are quickly reflected and summarized for NEO investors and researchers.
NeoGenomics reports that 2025 delivered 10% revenue growth and improved profitability metrics as the company deepened penetration in community oncology. Management highlights a full clinical launch of RaDaR® ST for MRD, expansion of the PanTracer therapy selection portfolio, targeted commercial hires, and a $30 billion combined addressable market for therapy selection and MRD.
Financially, revenue reached $727,332 (in thousands) in 2025 and adjusted EBITDA was $43,357 (in thousands); shares outstanding were 129,812,211 as of February 13, 2026. The company emphasizes continued R&D and commercial investment into 2026.
NeoGenomics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Proposals include electing nine directors, approving executive pay on an advisory basis, expanding the 2023 Equity Incentive Plan, and ratifying Deloitte & Touche LLP as auditor for 2026.
The equity plan amendment would increase shares reserved for issuance by 5,000,000 shares to a total of 13,300,000 shares, supporting future stock options and RSUs. As of March 23, 2026, 1,961,604 shares remained available and 13,934,021 options and stock awards were outstanding. The proxy also highlights strong board independence, share ownership guidelines, and extensive stockholder outreach on compensation and governance.
NeoGenomics Inc. President & Chief Operating Officer Warren Stone reported an equity compensation event on April 1, 2026. He exercised 17,562 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share.
Of these shares, 6,911 were disposed of through a tax-withholding transaction to satisfy tax obligations, a non-market event. Following these transactions, Stone directly holds 158,365 shares of NeoGenomics common stock, along with multiple outstanding stock option, restricted stock unit, and performance stock unit awards as listed in the filing.
NeoGenomics Inc. Chief Executive Officer Anthony P. Zook exercised equity awards and settled related taxes using shares. On April 1, 2026, he converted 140,498 restricted stock units into the same number of common shares at a $0.00 exercise price. Of these, 45,453 common shares were withheld to cover tax obligations, leaving 133,111 common shares held directly after the transactions, plus 18,900 shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust. He also continues to hold substantial stock options and restricted stock units granted in 2025 and 2026 that vest ratably over three years and have premium exercise prices based on 110% of the stock’s closing prices on the respective grant dates.
NeoGenomics Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of NeoGenomics common stock following an internal realignment.
The filing explains subsidiaries and business divisions of The Vanguard Group now report separately in reliance on SEC Release No. 34-39538, and Vanguard states it holds 0% of the class.
NeoGenomics Inc. Chief Accounting Officer Greg D. Aunan reported equity awards received on March 1, 2026. He was granted 36,825 stock options and 22,889 restricted stock units (RSUs), both with an exercise or acquisition price of $0.00 per share.
The stock options and RSUs each vest ratably over the first three anniversary dates of the grant date, meaning the awards vest in three equal annual installments. Once vested and settled into common shares, the shares of common stock are not subject to expiration. The filing also updates his directly owned option, RSU, and common stock balances as of the same date.
NeoGenomics Inc. executive vice president and general counsel Alicia C. Olivo reported new equity awards. On March 1, 2026, she received 147,804 stock options and 89,013 restricted stock units as compensation, both granted at an exercise/issue price of $0.00 per share.
The stock options are described as premium-price options, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest in equal installments over the first three anniversaries of the grant date, and once vested, the related common shares are not subject to expiration.
NeoGenomics Inc. reported that President & Chief Operating Officer Warren Stone received new equity awards. On March 1, 2026, he was granted 253,378 stock options and 152,594 restricted stock units, both vesting ratably over the first three anniversary dates of the grant.
The stock option grant was structured as a premium-price option, with the exercise price set at 110% of the February 27, 2026 closing share price. Footnotes also describe Mr. Stone’s existing stock options, restricted stock units, and performance stock units granted between 2022 and 2025, which vest over multi‑year and performance-based schedules.
NeoGenomics Inc. reported that Chief Executive Officer Anthony P. Zook received new equity awards. On March 1, 2026, he was granted 675,676 stock options and 406,918 restricted stock units at no cost per unit. The options are premium-price awards, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest ratably over the first three anniversaries of the grant date, tying most of the value to multi‑year service and performance. Once vested, the underlying common shares are not subject to expiration. Footnotes also reference earlier premium-price grants on April 1, 2025, indicating a continuing emphasis on performance-oriented, at-risk compensation for the CEO.
NeoGenomics Inc. Chief Financial Officer Abhishek Jain reported his initial equity holdings. On January 13, 2026, he was granted 183,578 stock options and 110,088 restricted stock units, which vest ratably over the first three anniversaries of the grant date. Once vested, the underlying common shares are not subject to expiration.